Home > Insider Trading > Filing (0001968202-24-000061)

Filing Details

Accession Number:: 0001968202-24-000061
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-02-12 16:02:02
Reporting Period:: 2024-02-09

Accepted Time:: 2024-02-12 16:02:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
872589	Regeneron Pharmaceuticals Inc.	REGN	Pharmaceutical Preparations (2834)	133444607

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1697422	R. Christopher Fenimore	777 Old Saw Mill River Road Tarrytown NY 10591	Svp Finance & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-02-09	344	$950.49	18,947	No	4	S	Direct
Common Stock	Disposition	2024-02-09	487	$951.39	18,460	No	4	S	Direct
Common Stock	Disposition	2024-02-09	1,046	$952.62	17,414	No	4	S	Direct
Common Stock	Disposition	2024-02-09	1,342	$953.47	16,072	No	4	S	Direct
Common Stock	Disposition	2024-02-09	1,100	$954.57	14,972	No	4	S	Direct
Common Stock	Disposition	2024-02-09	600	$955.00	14,372	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,473	Indirect	2021 GRAT
Common Stock	4,269	Indirect	2022 GRAT
Common Stock	1,499	Indirect	By 401(k) Plan
Common Stock	1,897	Indirect	By Trust
Common Stock	461	Indirect	by Trust for Daugh
Common Stock	460	Indirect	by Trust for Son

Footnotes

Represents volume-weighted average price of sales of 344 shares of Company stock on February 9, 2024 at prices ranging from $950.33 to $950.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
Represents volume-weighted average price of sales of 487 shares of Company stock on February 9, 2024 at prices ranging from $951.03 to $951.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
Represents volume-weighted average price of sales of 1,046 shares of Company stock on February 9, 2024 at prices ranging from $952.11 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
Represents volume-weighted average price of sales of 1,342 shares of Company stock on February 9, 2024 at prices ranging from $953.02 to $953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
Represents volume-weighted average price of sales of 1,100 shares of Company stock on February 9, 2024 at prices ranging from $954.00 to $954.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.